Abstract
Background. Previous studies have reported that glutathione plays a central role in a wide range of cellular functions, including protection, detoxification, transport, and metabolism. Buthionine sulfoximine (BSO), a specific inhibitor of γ‐glutamyl‐cysteine synthetase, depletes intracellular glutathione. The study investigates the cytotoxic effect of BSO and tumor necrosis factor‐α (TNF‐α) used in combination on TNF‐α‐resistant human renal and ovarian cancer cells. Methods. Cytotoxicity was determined by a 1‐day microculture tetrazolium dye assay. TNF‐α mRNA was examined by Northern blot analysis. Results. Combination treatment of TNF‐α‐resistant R4 and R11 human renal cell carcinoma cells with BSO and TNF‐α overcame their resistance to TNF‐α. In addition, the combination of BSO and TNF‐α resulted in a synergistic cytotoxic effect on TNF‐α‐resistant OVC‐8 and C30 human ovarian cancer cells. Treatment of R4, R11, and OVC‐8 cells with TNF‐α in combination with glutathione or N‐acetyl‐cysteine (NAC) showed an antagonistic cytotoxic effect. A possible mechanism of resistance to TNF‐α in tumor cells is the expression of TNF‐α mRNA or protein. R4 cells and OVC‐8 cells constitutively expressed mRNA for TNF‐α. Treatment of R4 cells or OVC‐8 cells with BSO down‐regulated the expression of TNF‐α mRNA; however, treatment with TNF‐α up‐regulated the expression of TNF‐α mRNA. When BSO was used in combination with TNF‐α, the level of TNF‐α mRNA enhanced by TNF‐α was markedly reduced. Incubation of R4 cells with glutathione or NAC also down‐regulated the expression of TNF‐α mRNA. R11 and C30 cells did not constitutively express mRNA for TNF‐α, and the BSO treatment had no effect on the TNF‐α mRNA level. Conclusions. This study demonstrates that the combination of BSO and TNF‐α can overcome the TNF‐α resistance of tumor cells and that depletion of intracellular glutathione and down‐regulation of TNF‐α mRNA by BSO may play a role in the enhanced cytotoxicity seen with the combination of BSO and TNF‐α. There may not be always a correlation between the expression of TNF‐α mRNA in tumor cells and their resistance to TNF‐α. The synergistic effect obtained with established renal cell carcinoma cells and ovarian cancer cells suggests that combination treatment with TNF‐α and BSO could have clinical application in the therapy of TNF‐α‐resistant tumors.

This publication has 29 references indexed in Scilit: